Nano-X Imaging Stock Plummets 21% After Mixed Earnings Report
Nano-X Imaging's stock experienced a significant drop of approximately 21% on Wall Street following the release of its second-quarter financial results. The company reported revenues that grew by over a third, reaching $4.16 million, a 37% increase year-over-year. However, this figure fell short of the $5.39 million expected by analysts, contributing to investor concerns.
Further compounding the issue, Nano-X Imaging reported a substantial increase in its net loss. The company posted a loss of $79 per share, significantly wider than the 16 cents per share loss anticipated by analysts. The total quarterly loss amounted to $55.5 million, partly due to a $40.7 million write-down of intangible assets. Adjusted EBITDA also rose to $11.3 million from $10.4 million in the same period last year, with adjusted net loss increasing to $11.6 million from $10.9 million.
Investor attention was also drawn to the company's declining cash reserves. The cash balance decreased by nearly half, from $60 million at the end of 2025 to $31.4 million by the end of June. While Nano-X Imaging raised an additional $8.5 million after the quarter's end through a direct offering and stock sale program, it indicated plans for further capital raises to bolster its balance sheet and fund operations.
Despite the financial challenges, Nano-X Imaging highlighted progress in its commercialization efforts. Its distribution network in the U.S. has expanded to ten partners, and its first Nanox Imaging Network site in Philadelphia has begun patient scans. The company has also started receiving insurance reimbursements for some scans. In the artificial intelligence sector, Nanox.AI secured a new agreement with Vertec Scientific in the UK and obtained a CMS reimbursement code, potentially boosting commercial adoption.
In an effort to manage its cash burn, the company is undertaking cost-reduction measures, including restructuring operations in South Korea. Nano-X Imaging aims to transition from systems in its sales backlog to active clinical use, believing that increased paid scans will validate its imaging model. Prior to this latest decline, the stock had already lost about 67% of its value since the start of 2026, indicating low investor confidence heading into the earnings report.
